Abstract
Objectives
The primary aim of the study was to gain insight into the relative risk of clinically relevant oral candidiasis following inhaled corticosteroid (ICS) initiation over time. A secondary aim was to analyse the influence of patient characteristics and co-medication on the occurrence of this adverse effect.
Methods
Drug prescription data from 1994 to 2011 were retrieved from the IADB.nl database. To study the influence of ICS use on occurrence of oral candidiasis, a prescription symmetry analysis was used, including patients using medication for oral candidiasis up to 1 year before or after ICS initiation. The relative risk was calculated by dividing the number of patients receiving medication for oral candidiasis after ICS initiation by the number of patients receiving the same medication before ICS initiation. Sub-analyses were conducted to compare the relative risks at several time points after ICS initiation and to account for therapy persistence by only including chronic users of ICS. A multivariate logistic regression model was used to identify predictive factors.
Results
A total of 52,279 incident users of ICS therapy were identified, of which 1,081 received medication for oral candidiasis up to 1 year before or after ICS initiation. A total of 701 patients received medication for oral candidiasis after ICS initiation, while 361 received these medications in the reversed sequence, resulting in a sequence ratio (SR) of 1.94 (95 % CI 1.71–2.21). In the first 3 months after ICS initiation, the SR was 2.72 (95 % CI 2.19–3.38) and then decreased to 1.47 (95 % CI 1.11–1.95) 9–12 months after ICS initiation. Predictive factors were higher daily dose of ICS and concomitant use of oral corticosteroids.
Conclusions
This study found a significant and clinically relevant increased number of patients receiving medication for oral candidiasis in the first year after therapy initiation with ICS. Relative risk is highest in the first 3 months, but remains increased up to at least 1 year after ICS initiation. This study stresses the need for patient education and inhalation instruction.
References
Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995;98(2):196–208.
Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126(1):213–9.
Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J. 1995;8(4):590–2.
Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy. 2006;61(5):518–26.
Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol. 2005;61(3):203–8.
Akpan A, Morgan R. Oral candidiasis. Postgrad Med J. 2002;78(922):455–9.
Groninger formularium. 6th ed. Groningen: KNMP departement Groningen; 2005.
Draijer LW. NHG-Farmacotherapeutische richtlijn Orale candidiasis. 2004; Available at: http://download.nhg.org/FTP_NHG/standaarden/FTR/Orale_candidiasis_text.html. Accessed 23 Apr 2012.
Milne LJ, Crompton GK. Beclomethasone dipropionate and oropharyngeal candidiasis. Br Med J. 1974;3(5934):797–8.
Vogt FC. The incidence of oral candidiasis with use of inhaled corticosteroids. Ann Allergy. 1979;43(4):205–10.
Dubus JC, Marguet C, Deschildre A, Mely L, Le Roux P, Brouard J, et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy. 2001;56(10):944–8.
Adams NP, Bestall JC, Jones PW, Lasserson TJ, Griffiths B, Cates C. Inhaled fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev 2005;(3):CD003534.
Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann Allergy Asthma Immunol. 2007;98(3):225–38.
Schirm E, Monster TB, de Vries R, van den Berg PB, de Jong-van den Berg LT, Tobi H. How to estimate the population that is covered by community pharmacies? An evaluation of two methods using drug utilisation information. Pharmacoepidemiol Drug Saf. 2004;13(3):173–9.
Tobi H, van den Berg PB, de Jong-van den Berg LT. The interaction database: synergy of science and practice in pharmacy. Med Data Anal. 2000;1933:206–11.
Vegter S, Nguyen NH, Visser ST, de Jong-van den Berg LT, Postma MJ, Boersma C. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care. 2011;17(9):609–16.
Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT, PREVEND Study Group Prevention of REnal and Vascular ENT Stage Disease. Pharmacy data in epidemiological studies: an easy to obtain and reliable tool. Pharmacoepidemiol Drug Saf. 2002;11(5):379–84.
Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology. 1996;7(5):478–84.
Hallas J, Bytzer P. Screening for drug related dyspepsia: an analysis of prescription symmetry. Eur J Gastroenterol Hepatol. 1998;10(1):27–32.
Vegter S, de Jong-van den Berg LT. Misdiagnosis and mistreatment of a common side-effect: angiotensin-converting enzyme inhibitor-induced cough. Br J Clin Pharmacol. 2010;69(2):200–3.
Tsiropoulos I, Andersen M, Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf. 2009;18(6):483–91.
Soysa NS, Samaranayake LP, Ellepola AN. Diabetes mellitus as a contributory factor in oral candidosis. Diabet Med. 2006;23(5):455–9.
Chattopadhyay A, Caplan DJ, Slade GD, Shugars DC, Tien HC, Patton LL. Risk indicators for oral candidiasis and oral hairy leukoplakia in HIV-infected adults. Community Dent Oral Epidemiol. 2005;33(1):35–44.
Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax. 1991;46(12):891–4.
Farrer M, Francis AJ, Pearce SJ. Morning serum cortisol concentrations after 2 mg inhaled beclomethasone dipropionate in normal subjects: effect of a 750 ml spacing device. Thorax. 1990;45(10):740–2.
Brown PH, Blundell G, Greening AP, Crompton GK. Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? Thorax. 1990;45(10):736–9.
Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593–604.
van‘t Veer NE, Lameijer W, De Ley M, Toben FM. Teaching to inhale: better utilization of powder inhalators after counseling and instruction. Ned Tijdschr Geneeskd. 2001;145(5):216–20.
Nimmo CJ, Chen DN, Martinusen SM, Ustad TL, Ostrow DN. Assessment of patient acceptance and inhalation technique of a pressurized aerosol inhaler and two breath-actuated devices. Ann Pharmacother. 1993;27(7–8):922–7.
Uijen JH, van Uijthoven YJ, van der Wouden JC, Bindels PJ. Adequate use of asthma inhalation medication in children: more involvement of the parents seems useful. BMC Res Notes. 2009;13(2):129.
Kamps AW, van Ewijk B, Roorda RJ, Brand PL. Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr Pulmonol. 2000;29(1):39–42.
Brand PL. Key issues in inhalation therapy in children. Curr Med Res Opin. 2005;21(Suppl. 4):S27–32.
Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care. 2005;50(10):1360–74. (discussion 1374–5).
Acknowledgments
The authors would like to thank Sipke Visser for data retrieval and technical support from the IADB.nl database.
Conflict of interest
All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no support from any organisation for the submitted work, no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years, and no other relationships or activities that could appear to have influenced the submitted work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van Boven, J.F.M., de Jong-van den Berg, L.T.W. & Vegter, S. Inhaled Corticosteroids and the Occurrence of Oral Candidiasis: A Prescription Sequence Symmetry Analysis. Drug Saf 36, 231–236 (2013). https://doi.org/10.1007/s40264-013-0029-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40264-013-0029-7